Serum degradome markers for the detection of breast cancer
- PMID: 20557135
- DOI: 10.1021/pr100395s
Serum degradome markers for the detection of breast cancer
Abstract
Many proteins have been proposed as potential biomarkers for breast cancer. Yet, validation of their discriminative value using quantitative methods has scarcely been performed. In this study, we investigated the discriminative value of six peptides that were previously proposed to be generated by breast cancer specific exoproteases: bradykinin, des-Arg(9)-bradykinin, Hyp(3)-bradykinin, and fragments of fibrinogen alpha-chain (Fib-alpha ([605-629])), complement component 4a (C4a ([1337-1350])), and interalpha trypsin inhibitor heavy chain 4 (ITIH4 ([666-687])). Their absolute serum concentrations were measured with a completely validated liquid chromatography-tandem mass spectrometric assay (LC-MS/MS) and compared between 62 newly diagnosed breast cancer patients and 62 controls matched for age and sample storage duration. Both ITIH4 ([666-687]) and des-Arg(9)-bradykinin showed statistically significantly higher median concentrations in breast cancer samples than in matched control samples. Additionally, we analyzed serum samples collected after surgical removal of the tumor, in which median ITIH4 ([666-687]) and des-Arg(9)-bradykinin concentrations were significantly decreased and not statistically significantly different from concentrations in the controls anymore. In a combined analysis, ITIH4 (666-687]) and des-Arg(9)-bradykinin independently contributed to the discrimination between cases and controls. In this study, we confirmed that the exoprotease breakdown peptides, ITIH4 (666-687]) and des-Arg(9)-bradykinin, differed between breast cancer cases and controls, supporting the potential of degradome markers for the diagnosis of breast cancer.
Similar articles
-
Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry.J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Feb 15;878(5-6):590-602. doi: 10.1016/j.jchromb.2010.01.011. Epub 2010 Jan 18. J Chromatogr B Analyt Technol Biomed Life Sci. 2010. PMID: 20116351
-
Sensitive liquid chromatography/tandem mass spectrometry assay for absolute quantification of ITIH4-derived putative biomarker peptides in clinical serum samples.Rapid Commun Mass Spectrom. 2010 Jul 15;24(13):1842-50. doi: 10.1002/rcm.4588. Rapid Commun Mass Spectrom. 2010. PMID: 20533314
-
The absolute quantification of eight inter-α-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients.Proteomics Clin Appl. 2010 Dec;4(12):931-9. doi: 10.1002/prca.201000035. Proteomics Clin Appl. 2010. PMID: 21137033
-
Early diagnostic protein biomarkers for breast cancer: how far have we come?Breast Cancer Res Treat. 2012 Jul;134(1):1-12. doi: 10.1007/s10549-011-1907-2. Epub 2011 Dec 17. Breast Cancer Res Treat. 2012. PMID: 22179926 Review.
-
Clinical proteomics in breast cancer: a review.Breast Cancer Res Treat. 2009 Jul;116(1):17-29. doi: 10.1007/s10549-008-0263-3. Epub 2008 Dec 11. Breast Cancer Res Treat. 2009. PMID: 19082706 Review.
Cited by
-
Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers.Clin Proteomics. 2010 Dec;6(4):115-127. doi: 10.1007/s12014-010-9054-z. Epub 2010 Sep 30. Clin Proteomics. 2010. PMID: 21124649 Free PMC article.
-
Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.Mol Cell Proteomics. 2017 Mar;16(3):386-406. doi: 10.1074/mcp.M116.063511. Epub 2017 Jan 4. Mol Cell Proteomics. 2017. PMID: 28062796 Free PMC article.
-
Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study.BMC Cancer. 2011 Aug 26;11:381. doi: 10.1186/1471-2407-11-381. BMC Cancer. 2011. PMID: 21871081 Free PMC article.
-
Low-mass-ion discriminant equation (LOME) for ovarian cancer screening.BioData Min. 2016 Oct 12;9:32. doi: 10.1186/s13040-016-0111-7. eCollection 2016. BioData Min. 2016. PMID: 27752286 Free PMC article.
-
Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2.Int J Oncol. 2019 Jul;55(1):131-141. doi: 10.3892/ijo.2019.4792. Epub 2019 May 2. Int J Oncol. 2019. PMID: 31059006 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous